

FORM PTO 1390
(REV 5-93)

US DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NUMBER
2001-0614ATRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. §371U.S. APPLICATION NO.
(if known, use 37 CFR 1.55)
[NEW] 097856061International Application No.
PCT/JP00/06351International Filing Date
September 18, 2000Priority Date Claimed
September 17, 1999**Title of Invention**

MAST CELL-SPECIFIC SIGNAL TRANSDUCER AND cDNA THEREOF

Applicant(s) For DO/EO/US



Ryo GOITSUKA

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. §371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. §371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. §371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☒ A translation of the International Application into English (35 U.S.C. §371(c)(2)). **ATTACHMENT A**
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3)).
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19.
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)). **ATTACHMENT B**
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)).

Items 11. to 14. below concern other document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98. **ATTACHMENT C**
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment. **ATTACHMENT D**
 - ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☒ Other items or information:
 - a. Cover page of Published International Application WO 01/21788 - **ATTACHMENT E**
 - b. International Search Report - **ATTACHMENT F**

U.S. APPLICATION NO. 09/856061 [NEW]		INTERNATIONAL APPLICATION NO. PCT/JP00/06351		ATTORNEY'S DOCKET NO. 2001_0614A							
15. [X] The following fees are submitted BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee nor international search fee paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00 International Search Report has been prepared by the EPO or JPO \$ 860.00 International preliminary examination fee not paid to USPTO but international search paid to USPTO \$ 710.00 International preliminary examination fee paid to USPTO but claims did not satisfy provisions of PCT Article 33(1)-(4) \$ 690.00 International preliminary examination fee paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$ 100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:50%;">CALCULATIONS</th> <th style="width:50%;">PTO USE ONLY</th> </tr> <tr> <td style="height: 100px;"></td> <td></td> </tr> <tr> <td>\$860.00</td> <td></td> </tr> </table>		CALCULATIONS	PTO USE ONLY			\$860.00	
CALCULATIONS	PTO USE ONLY										
\$860.00											
Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).											
Claims	Number Filed	Number Extra	Rate								
Total Claims	12 -20 =	0	X \$18.00								
Independent Claims	1 - 3 =	0	X \$80.00								
Multiple dependent claim(s) (if applicable)			+ \$270.00	\$							
TOTAL OF ABOVE CALCULATIONS =				\$860.00							
[] Small Entity Status is hereby asserted. Above fees are reduced by 1/2.											
SUBTOTAL =				\$860.00							
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+							
TOTAL NATIONAL FEE =				\$860.00							
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property				+							
TOTAL FEES ENCLOSED =				\$860.00							
				Amount to be refunded	\$						
				Amount to be charged	\$						
a. [X] A check in the amount of \$ 860.00 to cover the above fees is enclosed. A duplicate copy of this form is enclosed. b. [] Please charge my Deposit Account No. 23-0975 in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-0975.											
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.											
19. CORRESPONDENCE ADDRESS <div style="text-align: center;">  000513 PATENT TRADEMARK OFFICE </div>			By:  Matthew Jacob, Registration No. 25,154 WENDEROTH, LIND & PONACK, L.L.P. 2033 "K" Street, N.W., Suite 800 Washington, D.C. 20006-1021 Phone: (202) 721-8200 Fax: (202) 721-8250 May 17, 2001								

THE COMMISSIONER IS AUTHORIZED
 TO CHARGE ANY DEFICIENCY IN THE
 FEE FOR THIS PAPER TO DEPOSIT
 ACCOUNT NO. 23-0975.

[CHECK NO. 44510]

[2001_0614A]



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Ryo GOITSUKA

Attn: BOX PCT

Serial No. 09/856,061

Docket No. 2001_0614A

Filed May 17, 2001

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEE FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975.

MAST CELL-SPECIFIC SIGNAL TRANSDUCER AND
DNA THEREOF

[Corresponding to PCT/JP00/06351

Filed September 18, 2000]

PATENT OFFICE FEE TRANSMITTAL FORM

Assistant Commissioner for Patents,
Washington, DC 20231

Sir:

Attached hereto is a check in the amount of \$130.00 to cover Patent Office fees relating to filing the following attached papers:

Late filing of executed Declaration \$130.00

A duplicate copy of this paper is being submitted for use in the Accounting Division, Office of Finance.

The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.

07/13/2001 HNGUYEN 00000084 03856061

Respectfully submitted,

01 FC:154

130.00 CP

Ryo GOITSUKA

By Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicant

WMC/dlk
WENDEROTH, LIND & PONACK, L.L.P.
2033 K St., N.W., Suite 800
Washington, D.C. 20006-1021
Telephone (202) 721-8200
July 10, 2001

[Check No. 45375]
2001_0614A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

:

Ryo GOITSUKA

:

Attn: BOX PCT

Serial No. [NEW]

:

Docket No. 2001-0614A

Filed May 17, 2001

:

MAST CELL-SPECIFIC SIGNAL
TRANSDUCER AND cDNA THEREOF
[Corresponding to PCT/JP00/06351
Filed September 18, 2000]

:

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEE FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975.

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents,
Washington, DC 20231

Sir:

In the interest of compact prosecution and to reduce PTO filing fees, please amend the present application as follows:

IN THE CLAIMS:

Please amend claims 7 and 8 as follows:

7. (Amended) A cell transformed with the expression vector of claim 5.

8. (Amended) A cell transformed with the expression vector of claim 6.

Please add the following new claims:

11. (New) A cell transformed with an expression vector of claim 5 which produces a protein having the amino acid sequence of SEQ ID No. 2.

ATTACHMENT D

12. (New) A cell transformed with an expression vector of claim 6 which produces a protein having the amino acid sequence of SEQ ID No. 4.

REMARKS


The above amendment is presented to eliminate multiple dependent claims, thereby reducing PTO filing fees.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is entitled "**Version with Markings to Show Changes Made**".

Favorable action on the merits is now requested.

Respectfully submitted,

Ryo GOITSUKA

By 
Matthew Jacob
Registration No. 25,154
Attorney for Applicant

MJ/pjm
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
May 17, 2001

Version with Markings to Show Changes Made

Claims 7 and 8 have been amended as follows:

7. **(Amended)** A cell transformed with the expression vector of claim 5[, which produces the protein of claim 1].

8. **(Amended)** A cell transformed with the expression vector of claim 6[, which produces the protein of claim 2].

09/856061

DESCRIPTION**Mast Cell-Specific Signal Transducer
and cDNA thereof****Technical Field**

The present invention relates to a signal transducer specifically expressed in mouse and human mast cell, and polynucleotides (cDNAs) encoding this protein molecule. More particularly, the present invention relates to a novel protein that is useful, for example, as a target molecule for screening a therapeutic agent for allergic diseases, and various genetic engineering materials useful for production and functional analysis of this protein.

Background Art

The type-I allergic response is a complicated immune reaction induced by release of granules containing histamine and serotonin through cross-linking of high affinity IgE receptors mainly expressed in the mast cell and basophilic leukocytes with IgE antibodies and allergens.

This reaction has been elucidated to be composed of the following three stages:

A) An initial stage including production of cytokines such as IL-4 and IL-5 from T cell by stimulation of allergens, production of the IgE antibody from B cell, and differentiation and proliferation of the mast cells induced by production of the cytokines;

B) An intermediate stage from cross-linking of Fcε receptors by the IgE antibody and allergen to degranulation of the mast cell; and

C) A later stage such as enhanced vascular permeability by

10

5

15

20

30

encoding these protein molecules.

Another object of the present invention is to provide various genetic engineering materials involved in the signal transducers.

5

Disclosure of Invention

For solving the problems above, the present invention provides the following inventions (1) to (10).

10

(1) A signal transducer specifically expressed in mouse mast cells, which is a purified protein having the amino acid sequence of SEQ ID No. 2.

15

(2) A signal transducer specifically expressed in human mast cells, which is a purified protein having the amino acid sequence of SEQ ID No. 4.

(3) A polynucleotide consisting of the base sequence of SEQ ID No. 1, which encodes the protein of (1).

20

(4) A polynucleotide having the base sequence of SEQ ID No. 3, which encodes the protein of (4).

25

(5) An expression vector involving the polynucleotide of (3).

(6) An expression vector involving the polynucleotide of (4).

(7) A cell transformed with the expression vector of (5), which produces the protein of (6).

30

(8) A cell transformed with the expression vector of (6), which

produces the protein of (2).

(9) An antibody against the protein of (1).

5 (10) An antibody against the protein of (2).

Brief Description of the Drawings

10 Fig. 1 shows the results of Northern blot analysis investigating expression of MIST, BASH and SLP-76 in the hemopoietic and non-hemopoietic cell lines. 18-18: B-precursor cells, WEHI1279: B cells, L1210: B-lymphocyte precursor cells, JS58L and P3U1: plasma cells, EL-4 and BW5147: T cells, P388D1 and WEHI3: macrophages, P815: mast
15 cell, B8/3: erythroblast, and B16,Y1, NIH3T3 and ES-E14: non-hemopoietic cell lines.

Fig. 2 shows the results of RT-PCR analysis investigating expression of MIST in various hemopoietic cell lines.

20 Figs. 3 and 4 show the results of immunohistological analysis investigating expression of MIST in inflammatory mast cell in atopic dermatitis of the NC/Nga mouse.

25 Fig. 5 shows the results of degranulation reaction of RBL-2H3 clone expressing wild-type or mutant MIST.

Best Mode for Carrying Out the Invention

30

By screening the expression sequence tag (EST) database, the present inventor identified an EST clone from 13.5 day mouse embryo cDNA library (GenBank accession No. AA166259) which showed a

significant amino acid homology to the SH2 domain of chicken BASH (J. Immunol. 161:5804-5808, 1998). The inventor further found that the 1.8 kb mRNA of this clone is not expressed in other hemopoietic cell lines and non-hemopoietic cell lines (such as B cell, T cell and macrophages) in which BASH and SLP-76 are expressed, and is expressed only in mastcytoma cell line P815 (Fig. 1). The expressed protein molecule was named as MIST (Mast Cell-specific Immunoreceptor Signal Transducer) form such specific expression pattern and its function to be described hereinafter.

Embodiments of the present invention will be described in detail hereinafter.

The MISTs according to the inventions (1) and (2) are proteins that are specifically expressed in mouse and human mast cells. The mouse MIST in the invention (1) is a protein encoded in the polynucleotide (full-length cDNA: SEQ ID No. 1) of the invention (3). The human MIST in the invention (2) is, on the other hand, a protein encoded in the polynucleotide of the invention (4) containing the sequence of SEQ ID No. 3 (a partial cDNA).

While the mouse MIST in the invention (1) and human MIST in the invention (2) may be obtained by a method for isolating from organs and cell lines of mouse and human, respectively, by a method for preparing a peptide by a chemical synthesis based on the amino acid sequences provided by the present invention, or by a production method using a recombinant DNA technology using the polynucleotides of the inventions (3) and (4), the recombinant DNA method is preferably used. For example, RNA is prepared by in vitro transcription from a vector having the polynucleotides of the inventions (3) and (4), and MIST is expressed in vitro by in vitro translation using the RNA as a template. The mouse MIST and human MIST encoded by the polynucleotide can be expressed in large scale in prokaryotic cells such as E. coli and Bacillus subtilis, and

in eukaryotic cells such as yeast, insect cells, mammal cells and plant cells by recombination of the coding region with the expression vector using a conventional method.

5 The polynucleotide (SEQ ID No. 1) of the invention (3) can be obtained by a chemical synthesis or screening of the mouse cDNA library. For cloning the desired polynucleotide from a cDNA library, an oligonucleotide is synthesized based on the base sequence in an arbitrary portion of SEQ ID No. 1, and the polynucleotide is screened by colony or
10 plaque hybridization by the method known in the art using the oligonucleotide as a probe. Alternatively, oligonucleotides that can hybridize to both ends of the desired polynucleotide are synthesized, and the polynucleotide of the invention (3) is prepared by a PCR method using the oligonucleotides as primers and genomic DNA isolated from the
15 mouse cells as a template.

20 The polynucleotide of the invention (4) can be prepared by isolating a full-length cDNA by hybridization screening or PCR using the oligonucleotides synthesized based on the base sequence at an arbitrary portion of SEQ ID No. 3.

25 For producing the MIST by expressing the polynucleotide in vitro translation, for example, the polynucleotide of the invention (3) or (4) is recombined into a vector having a RNA polymerase promoter [the inventions (5) and (6)], and the recombinant vector is added to an in vitro translation system such as a lysate of rabbit reticulocytes or wheat germ extract containing the RNA polymerase corresponding to the promoter, thereby producing the mouse and human MIST in vitro. Examples of the RNA polymerase promoters include T7, T3 and SP6. Examples of the
30 vectors containing the RNA polymerase are pKA1, pCDM8, pT3/T7 18, pT7/3 19 and pBluescript II.

For producing the MIST by expressing the polynucleotide in

microorganisms such as *E. coli*, an expression vector [the invention (5) and (6)] is prepared by recombining the polynucleotide of the invention (3) or (4) into an expression vector having an origin capable of replication in microorganisms, a promoter, a ribosome binding site, DNA cloning sites and terminator. After transforming host cell with this expression vector, the transformant obtained [the inventions (7) and (8)] is cultured for large scale production of MIST encoded by these polynucleotides in microorganisms. MIST fragments containing arbitrary regions may be obtained by adding an initiation codon and a termination codon before and after the arbitrary coding region. Or, the protein can be expressed as a fusion protein with other proteins. Only the protein regions encoded by this cDNA may be obtained by cleaving the fusion protein with an appropriate protease. Examples of the expression vector for use in *E. coli* include a pUC series vector, pBluescript II, pET expression system and pGEX expression system.

For producing the MIST by expressing the polynucleotide in eukaryotic cell, the polynucleotide of the invention (3) or (4) is recombined with an expression vector for eukaryotic cells that comprises a promoter, splicing site, poly(A) additional site to prepare a recombinant vector [the inventions (5) and (6)], and the vector is introduced into the eukaryotic cell to transform a host cell [the inventions (7) and (8)]. Examples of the expression vectors include pKA1, pCDM8, pSVK3, pMSG, pSVL, pBK-CMV, pBK-RSV, EBV vector, pRS and pYES2. MIST may be expressed as a fusion protein to which various tags such as His tag, FLAG tag and GFP by using pIND/V5-His, pFLAG-CMV-2, pEGFP-N1 and pEGFP-C1 as an expression vector. While cultured cells of a mammal such as monkey kidney cells COS7 and Chinese hamster ovary cells CHO, budding yeast, dividing yeast, silkworm cells and African clawed frog egg cells are usually used as the eukaryotic cells, any eukaryotic cells may be used so long as they are able to express MIST. The expression vector can be introduced into the eukaryotic cell by a conventional method such as an electroporation method, a calcium phosphate method, a liposome

method, and a DEAE dextran method.

A combination of separation methods known in the art may be used for purifying the desired protein from the culture after allowing
5 MIST to express in the prokaryotic cells and eukaryotic cells. For example, these methods include treatment with a denaturation reagent such as urea or with a surface active agent, ultrasonic treatment, enzymatic digestion, salting-out and solvent precipitation method, dialysis, centrifugation, ultrafiltration, gel filtration, SDS-PAGE,
10 isoelectric focusing electrophoresis, ion exchange chromatography, hydrophobic chromatography, affinity chromatography and reversed phase chromatography.

The mouse MIST of the invention (1) and the human MIST of the
15 invention (2) contain any peptide fragments (five amino acid residues or more) represented by SEQ ID Nos. 2 and 4. These peptide fragments may be used for preparing antibodies. The MISTs of the inventions (1) and (2) are modified in any ways in the cell after translation. Accordingly, these modified proteins are also included within the scope of
20 the present invention. Examples of modification after translation include elimination of N-terminal methionine, N-terminal acetylation, addition of sugar chains, restricted degradation by an intracellular protease, addition of miristoleic acid, isoprenylation and phosphorylation.

Polymorphism by individual differences is often observed in the animal gene. Accordingly, polynucleotides having addition or deletion of one or plural nucleotides and/or substitution with other nucleotides in the base sequence of SEQ ID Nos. 1 and 3 are also included within the
30 scope of the present invention.

Likewise, MISTs having addition or deletion of one or plural amino acids and/or substitution with other amino acids caused by the

alteration of polynucleotides as described above are also included within the scope of the present invention so long as it has an activity of the MIST containing the amino acid sequences of SEQ ID Nos. 2 and 4.

5 The polynucleotides in the inventions (3) and (4) also include DNA fragments (10 bp or more) comprising any partial base sequence of SEQ ID Nos. 1 and 3. DNA fragments comprising sense strand and antisense strands are also included within the scope as described above.

10 The antibodies according to the inventions (9) and (10) can be obtained from serums of an animals immunized with the proteins of the inventions (1) and (2). Chemically synthesized peptides based on the amino acid sequences of SEQ ID Nos. 2 and 4, and MIST itself expressed in the eukaryotic or prokaryotic cells may be used for the antigen.
15 Otherwise, the antibodies may be produced from collected serums after introducing the expression vector for the eukaryotic cell into the muscle or skin of an animal by injection or using a gene gun (for example, the method described in Japanese Patent Publication No. 7-31387). The animals used include mouse, rat, rabbit, goat and chicken. Monoclonal
20 antibodies against MIST can be obtained by preparing a hybridoma by fusing B cell extracted from an immunized animal with myeloma cells.

Examples

25

The present invention is described in more detail with Examples, the present invention is not restricted in any sense by the Examples as set forth below.

30

Example 1: cDNA cloning

Full-length mouse MIST cDNA was isolated from PT18 cDNA

library with 5'- and 3'-RACE (Marathon cDNA amplification kit, made by Clontech Co.), using primers prepared based on the sequence information of EST clone (GenBank accession No. AA166259). The partial cDNA of human MIST was amplified by PCR using mRNA prepared from human
 5 cord blood mast cell (HCMC) cultured with IL-6 and the stem cell factor (SFC: Peprotech) according to the method in "Blood 86:3705-3714, 1995.

The sequence of the cDNA obtained was determined by the method known in the art, confirming that the mouse MIST cDNA comprises the
 10 base sequence represented by SEQ ID No. 1 and the human MIST partial cDNA comprises the base sequence represented by SEQ ID No. 3. It was also confirmed that the mouse MIST has the amino acid sequence represented by SEQ ID No. 2 with a molecular weight of about 60 kDa. Eight Tyr residues capable of phosphorylation are found in the mouse
 15 MIST from the N-terminus to the central part. The C-terminal part contains an SH2 domain which is most similar to the SH2 domain of mouse BASH and SLP-76 in amino acid level (41% and 53% identities, respectively). In addition, the central part of MIST is rich in Pro residues, and contains SH3 domain-binding motif. Consequently, MIST was
 20 confirmed to have the features as a signal molecule.

The human MIST showed, on the other hand, 60% homology with the mouse MIST in the amino acid level.

Example 2: Construction of expression vector

The coding region of the mouse MIST cDNA obtained in Example 1 was amplified by PCR, and the amplified region was inserted between the
 30 EcoRI and Sal I sites of pCATneo expression vector (J. Immunol., 161:5804-5808, 1998) to construct a recombinant expression vector (pCATneo-MIST-WT).

The MIST mutant (MIST-YF) in which amino acids (Tyr) at 69, 96, 101, 153, 174 and 188 in SEQ ID No. 2 were substituted with other amino acids (Phe) was prepared by a PCR-based mutagenesis using a commercially available mutation kit (made by Stratagene Co.), and subcloned the MIST-YF into the pCATneo to construct a recombinant expression vector (pCATneo-MIST-YF).

Example 3: Preparation of transformed cells

The rat mast cell line RBL-2H3 were transfected with the recombinant expression vectors pCATneo-MIST or pCATneo-MIST-YF prepared in Example 2 to prepare the transformed cell RBL-2H3-MIST and RBL-2H3-MIST-YE.

Example 4: Preparation of antibody

An anti-MIST antibody was prepared from a rabbit immunized with a fusion protein of a polypeptide comprising the amino acid sequence 193-435 in SEQ ID No. 2 and glutathione-S-transferase (GST). The antisera were at first precleared with Sepharose beads coupled with GST alone, and then purified with an affinity column coupled with GST-MIST fusion protein. Specificity of the antibody purified with affinity chromatography was confirmed by an immunoblot analysis on cell lysates from COS cells transfected with mouse MIST cDNA.

Example 5: Confirmation of MIST expression in various cell lines

Expression of the mouse and human MISTs obtained in Example 1 was confirmed by RT-PCR. The objective cells were IL-3-induced mouse bone marrow-derived mast cells (BMMC), mouse mast cell line PT18,

human mast cells (HCNC) cultured with SCF and IL-6, and other hemocyte cell lines (Jurkat: human T cell, Romas: human B cell, KU812: human basophil precursor cell, EOL-1: human eosinophil precursor cell).

5 The results are as shown in Fig. 2. Although expression of MIST was found in mast cells BMMC, PT18 and HCNC, other cell lines showed no expression.

10 By using the anti-MIST antibody prepared in Example 4, serial tissue sections of NC/Nga mice, which spontaneously develop atopic dermatitis (J. Immunol., 9:461-466, 1997) were stained to clarify whether MIST protein is expressed in normal mast cells in vivo. The results are shown in Figs. 3 and 4. Expression of MIST was observed in the inflammatory mast cells in the mouse.

15 It was confirmed from the results as described above that MIST is a protein specifically expressed in mast cell.

20 Example 6: Confirmation of phosphorylation of tyrosine in MIST

Phosphorylation of tyrosine in MIST by stimulating with FcεRI was investigated using the rat mast cell line RBL-2H3 in which signal transduction of FcεRI had been confirmed.

25 The transformed cell RBL-2H3-MIST prepared in Example 3 was cultured with 10 μg of anti-DNP mouse IgE (made by Sigma Co.) for 1 hour, and the cells were stimulated with 100 ng/ml of DNP-HSA. The cells were lysed with 1% NP40 lysis buffer, and the lysate was subjected to immune precipitation together with various antibodies.

Tyrosine of the MIST molecule was phosphorylated by stimulating the Fcε receptor on the mast cell IgE and antigens, and MIST associate

with signal molecules such as PLC- γ and Vav. Consequently, the MIST molecule was confirmed to be a signal molecule existing at the downstream of the Fc ϵ receptor. MIST was evidently phosphorylated by Lyn kinase among tyrosine kinases present in the mast cell, showing that the Lyn kinase has an important role for degranulation of the mast cell.

Example 7: Investigation of MIST function in degranulation of mast cell

The effect of over expression of MIST and mutation type MIST on degranulation of the cells was investigated using the transformed cells, RBL-2H3-MIST and RBL-2H3-MIST-YF prepared in Example 3.

The cells were cultured with 1 μ g/ml of anti-DNP mouse IgE overnight, washed twice with PBS, and stimulated with DNP-HSA at 37°C for 30 minutes. Degranulation was confirmed by measuring release of β -hexosaminidase by the method described in the literature (Int. Immunol., 7:251-258, 1992).

The results are shown in Fig. 5. Although degranulation of the mast cell was not affected by stimulation with the Fc ϵ receptor when a wild type MIST was over expressed, degranulation of the mast cell via the Fc ϵ receptor was significantly suppressed by over expression of the MIST mutant (MIST-YF).

It was confirmed from the results above that the MIST molecule plays an important role in the signal transduction pathway from stimulation by the Fc ϵ receptor through degranulation.

Industrial Applicability

The present invention provides signal transducers that are

specifically expressed in mouse and human mast cells, polynucleotides (cDNAs) encoding this protein molecule and various gene engineering materials concerning these signal transducers. Screening of novel agents for allergic diseases becomes possible by using these signal

5 transducers as targets.

[illegible]

CLAIMS

1. A signal transducer specifically expressed in mouse mast cells,
which is a purified protein having the amino acid sequence of SEQ ID No.

2.

2. A signal transducer specifically expressed in human mast cells,
which is a purified protein having the amino acid sequence of SEQ ID No.

4.

3. A polynucleotide consisting of the base sequence of SEQ ID No. 1,
which encodes the protein of claim 1.

4. A polynucleotide having the base sequence of SEQ ID No. 3, which
encodes the protein of claim 2.

5. An expression vector involving the polynucleotide of claim 3.

6. An expression vector involving the polynucleotide of claim 4.

7. A cell transformed with the expression vector of claim 5, which
produces the protein of claim 1.

8. A cell transformed with the expression vector of claim 6, which
produces the protein of claim 2.

9. An antibody against the protein of claim 1.


10. An antibody against the protein of claim 2.

ABSTRACT

The present invention provides a signal transducer specifically expressed in mouse mast cells that has the amino acid sequence of SEQ ID No. 2, a signal transducer specifically expressed in human mast cells that has the amino acid sequence of SEQ ID No. 4, polynucleotides encoding these proteins, an expression vector involving these polynucleotides, transformed cells induced by these expression vectors, and antibodies against the foregoing proteins. The signal transducer provided in the present invention is useful for screening of novel medicines against allergic diseases.

1/3

Fig. 1



2/3

Fig. 2




Fig. 3




Fig. 4



3/3

Fig. 5



DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATION

() Original () Supplemental () Substitute (X) PCT () DESIGN

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Title: MAST CELL-SPECIFIC SIGNAL TRANSDUCER AND cDNA THEREOF

of which is described and claimed in:

() the attached specification, or

() the specification in application Serial No. _____, filed _____, and with amendments through _____, or

(X) the specification in International Application No. PCT/JP00/06351, filed September 18, 2000, and as amended on _____ (if applicable).

I hereby state that I have reviewed and understand the content of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge my duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim priority benefits under Title 35, United States Code, §119 (and §172 if this application is for a Design) of any application(s) for patent or inventor's certificate listed below and have also identified below any application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:


COUNTRY	APPLICATION NO.	DATE OF FILING	PRIORITY CLAIMED
Japan	1999-263778	September 17, 1999	Yes

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	U.S. FILING DATE	STATUS: PATENTED, PENDING, ABANDONED

And I hereby appoint Michael R. Davis, Reg. No. 25,134; Matthew M. Jacob, Reg. No. 25,154; Warren M. Cheek, Jr., Reg. No. 33,367; Nils Pedersen, Reg. No. 33,145; Charles R. Watts, Reg. No. 33,142; and Michael S. Huppert, Reg. No. 40,268, who together constitute the firm of WENDEROTH, LIND & PONACK, L.L.P., as well as any other attorneys and agents associated with Customer No. 000513, to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

I hereby authorize the U.S. attorneys and agents named herein to accept and follow instructions from NISHIZAWA & ASSOCIATES as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and myself. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by me.

Direct Correspondence to Customer No: <div style="text-align: center;">  000513 PATENT TRADEMARK OFFICE </div>		Direct Telephone Calls to: WENDEROTH, LIND & PONACK, L.L.P. 2033 "K" Street, N.W., Suite 800 Washington, D C 20006-1021 Phone: (202) 721-8200 Fax: (202) 721-8250		
---	--	--	--	--

Full Name of First Inventor	FAMILY NAME GOITSUKA	FIRST GIVEN NAME Ryo	SECOND GIVEN NAME
Residence & Citizenship	CITY Tokyo	STATE OR COUNTRY Japan	COUNTRY OF CITIZENSHIP Japan
Post Office Address	ADDRESS 48-4-705, Sendagi 2-chome, Bunkyo-ku, Tokyo, JAPAN	CITY	STATE OR COUNTRY ZIP CODE

Full Name of Second Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE

Full Name of Third Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE

Full Name of Fourth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE

Full Name of Fifth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE

I further declare that all statements made herein of my own knowledge are true, and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1st Inventor Ryo Goitsuka Date June 22, 2001
Ryo GOITSUKA
2nd Inventor _____ Date _____
3rd Inventor _____ Date _____
4th Inventor _____ Date _____
5th Inventor _____ Date _____
6th Inventor _____ Date _____

The above application may be more particularly identified as follows:

U.S. Application Serial No. _____ Filing Date May 17, 2001

Applicant Reference Number 00-F-047PCT-US/YS Atty Docket No. 2001-0614A

Title of Invention MAST CELL-SPECIFIC SIGNAL TRANSDUCER AND cDNA THEREOF

SEQUENCE LISTING

<110> Japan Science and Technology Corporation

<120> A mast cell-specific adapter molecules and cDNAs thereof

<130> 00-F-047PCT/YS

<140> PCT/JP00/06351

<141> 2000-9-17

<150> JP11-263778

<151> 1999-09-17

<160> 4

<170> PatentIn Ver. 2.0

<210> 1

<211> 1721

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (255).. (1562)

<300>

<301> Goitsuka R., et al.

<302> A BASH/SLP-76-related adaptor protein MIST/Clink involved in IgE
receptor-mediated mast cell degranuation

<303> Int. Immunol.

<304> 12

<305> 4

<306> 573-580

<307> 2000

<308> GenBank/AB021220

<309> 2000-05-26

<400> 1

```

acgaggccaa actgccagg tctgtgctg cgtttctcg aaaacaaaa ctcaacaggc 60
acatacaagg cactctctgc tgaaggactc lgtgagggg agagaacatg tcaactctat 120
cttacagagt gctccaggat gcgaccgtgg accccctttc caggagctag ccgtctcaac 180
actgagccct tgactaaagg aagactgagc aggctgagtt gaagatccct ctcttttgcc 240
aggtgccaaag gacc atg acc agc cag ggc aat aaa agg aca acg aaa gaa 290
      Met Thr Ser Gln Gly Asn Lys Arg Thr Thr Lys Glu
              1           5           10
gga ttc ggt gat ctg aga ttc cag aac gtc tct ctg ctg aaa aat agg 338
Gly Phe Gly Asp Leu Arg Phe Gln Asn Val Ser Leu Leu Lys Asn Arg
      15           20           25
tca tgg cca agc ctc agc agt gcc aaa ggg cgg tgt cga gcg gtt ctg 386
Ser Trp Pro Ser Leu Ser Ser Ala Lys Gly Arg Cys Arg Ala Val Leu
      30           35           40
gaa cca ctt ccg gat cac aga agg aac ttg gct ggg gtc cca ggt gga 434
Glu Pro Leu Pro Asp His Arg Arg Asn Leu Ala Gly Val Pro Gly Gly
      45           50           55           60
gaa aaa tgc aac agt aac aac gac tac gaa gat cct gag ttc cag ctg 482
Glu Lys Cys Asn Ser Asn Asn Asp Tyr Glu Asp Pro Glu Phe Gln Leu
      65           70           75
ctg aag gca tgg cca tca atg aaa att tta cca gcc aga cct atc cag 530

```

Leu Lys Ala Trp Pro Ser Met Lys Ile Leu Pro Ala Arg Pro Ile Gln
 80 85 90
 gaa tcg gaa tac gca gat aca cgc tat ttc cag gat atg atg gag gct 578
 Glu Ser Glu Tyr Ala Asp Thr Arg Tyr Phe Gln Asp Met Met Glu Ala
 95 100 105
 ccc ctt ctg tta cct ccc aag gct tct gtc tcc act gag aga caa acc 626
 Pro Leu Leu Leu Pro Pro Lys Ala Ser Val Ser Thr Glu Arg Gln Thr
 110 115 120
 agg gat gtg agg atg aca cag ctg gaa gaa gtg gac aag cct acc ttc 674
 Arg Asp Val Arg Met Thr Gln Leu Glu Glu Val Asp Lys Pro Thr Phe
 125 130 135 140
 aag gat gtc aga agc caa cgc ttt aaa gga ttc aaa tac aca aaa ata 722
 Lys Asp Val Arg Ser Gln Arg Phe Lys Gly Phe Lys Tyr Thr Lys Ile
 145 150 155
 aac aag act cct ttg cca cct cct cgg cct gct atc act ctc ccc aag 770
 Asn Lys Thr Pro Leu Pro Pro Pro Arg Pro Ala Ile Thr Leu Pro Lys
 160 165 170
 aag tac caa ccc tta ccc cca gca cca cca gag gag agc agt gca tac 818
 Lys Tyr Gln Pro Leu Pro Pro Ala Pro Pro Glu Glu Ser Ser Ala Tyr
 175 180 185
 ttc gct cca aag ccc acc ttt cca gaa gtc cag agg ggg ccc agg cag 866
 Phe Ala Pro Lys Pro Thr Phe Pro Glu Val Gln Arg Gly Pro Arg Gln
 190 195 200
 agg agt gca aaa gac ttc agt agg gtc ctt gga gca gaa gaa gaa tct 914
 Arg Ser Ala Lys Asp Phe Ser Arg Val Leu Gly Ala Glu Glu Glu Ser
 205 210 215 220
 cac cac cag aca aag cca gaa tct tct tgc cca tca tca aac caa aac 962
 His His Gln Thr Lys Pro Glu Ser Ser Cys Pro Ser Ser Asn Gln Asn

225	230	235	
ada cag aag agt cca cct gcc att gcc agc tct tcc tac atg cca gga	1010		
Thr Gln Lys Ser Pro Pro Ala Ile Ala Ser Ser Ser Tyr Met Pro Gly			
240	245	250	
aag cac agt ata caa gcc aga gac cat aca ggt agc atg cag cac tgt	1058		
Lys His Ser Ile Gln Ala Arg Asp His Thr Gly Ser Met Gln His Cys			
255	260	265	
cct gct cag aga tgc caa gct gca gcc agc cac agc cct cga atg ctg	1106		
Pro Ala Gln Arg Cys Gln Ala Ala Ala Ser His Ser Pro Arg Met Leu			
270	275	280	
ccc tat gaa aac aca aac tgc gag aaa cct gac ccc aca aag cct gat	1154		
Pro Tyr Glu Asn Thr Asn Ser Glu Lys Pro Asp Pro Thr Lys Pro Asp			
285	290	295	300
gag aag gat gtc tgg cag aat gaa tgg tac att gga gaa tac agt cgc	1202		
Glu Lys Asp Val Trp Gln Asn Glu Trp Tyr Ile Gly Glu Tyr Ser Arg			
305	310	315	
cag gca gtg gaa gat gtg tta atg aaa gag aac aag gat ggt act ttt	1250		
Gln Ala Val Glu Asp Val Leu Met Lys Glu Asn Lys Asp Gly Thr Phe			
320	325	330	
ttg gtc cga gac tgc tct aca aaa tcc aag gca gaa cca tat gtt ttg	1298		
Leu Val Arg Asp Cys Ser Thr Lys Ser Lys Ala Glu Pro Tyr Val Leu			
335	340	345	
gtg gtg ttt tat ggg aac aag gtc tac aat gtg aaa atc cgt ttc ctc	1346		
Val Val Phe Tyr Gly Asn Lys Val Tyr Asn Val Lys Ile Arg Phe Leu			
350	355	360	
gag agc aat caa cag ttt gcc ctg ggc aca gga cta cga gga aat gag	1394		
Glu Ser Asn Gln Gln Phe Ala Leu Gly Thr Gly Leu Arg Gly Asn Glu			
365	370	375	380

5/13

atg ttt gat tct gtg gaa gac atc att gaa cac tac aca tat ttt ccc 1442

Met Phe Asp Ser Val Glu Asp Ile Ile Glu His Tyr Thr Tyr Phe Pro

385

390

395

att ctg cta ata gat ggg aaa gac aag gct gca cgc agg aaa cag tgc 1490

Ile Leu Leu Ile Asp Gly Lys Asp Lys Ala Ala Arg Arg Lys Gln Cys

400

405

410

tac ctc acc cag cca ctg cct ctc gcc agg ctc ctt ctc act cag tac 1538

Tyr Leu Thr Gln Pro Leu Pro Leu Ala Arg Leu Leu Leu Thr Gln Tyr

415

420

425

tcc agc cag gca ctt cat gag taa gaagcccagc cagatatccc cgcattcagt 1592

Ser Ser Gln Ala Leu His Glu

430

435

gcctgggcct tgtctcattc ctggctcaat ggattcagtt cttcttccat ctgcatttat 1652

ctgcaaagta ttattttctg tgtcttcaag ggaatgatitt ttgactctgt aaaaaaaaaa 1712

aaaaaaaaa

1721

<210> 2

<211> 435

<212> PRT

<213> Mus musculus

<400> 2

Met Thr Ser Gln Gly Asn Lys Arg Thr Thr Lys Glu Gly Phe Gly Asp

1

5

10

15

Leu Arg Phe Gln Asn Val Ser Leu Leu Lys Asn Arg Ser Trp Pro Ser

20

25

30

Leu Ser Ser Ala Lys Gly Arg Cys Arg Ala Val Leu Glu Pro Leu Pro

35

40

45

6/13

Asp His Arg Arg Asn Leu Ala Gly Val Pro Gly Gly Glu Lys Cys Asn
50 55 60
Ser Asn Asn Asp Tyr Glu Asp Pro Glu Phe Gln Leu Leu Lys Ala Trp
65 70 75 80
Pro Ser Met Lys Ile Leu Pro Ala Arg Pro Ile Gln Glu Ser Glu Tyr
85 90 95
Ala Asp Thr Arg Tyr Phe Gln Asp Met Met Glu Ala Pro Leu Leu Leu
100 105 110
Pro Pro Lys Ala Ser Val Ser Thr Glu Arg Gln Thr Arg Asp Val Arg
115 120 125
Met Thr Gln Leu Glu Glu Val Asp Lys Pro Thr Phe Lys Asp Val Arg
130 135 140
Ser Gln Arg Phe Lys Gly Phe Lys Tyr Thr Lys Ile Asn Lys Thr Pro
145 150 155 160
Leu Pro Pro Pro Arg Pro Ala Ile Thr Leu Pro Lys Lys Tyr Gln Pro
165 170 175
Leu Pro Pro Ala Pro Pro Glu Glu Ser Ser Ala Tyr Phe Ala Pro Lys
180 185 190
Pro Thr Phe Pro Glu Val Gln Arg Gly Pro Arg Gln Arg Ser Ala Lys
195 200 205
Asp Phe Ser Arg Val Leu Gly Ala Glu Glu Glu Ser His His Gln Thr
210 215 220
Lys Pro Glu Ser Ser Cys Pro Ser Ser Asn Gln Asn Thr Gln Lys Ser
225 230 235 240
Pro Pro Ala Ile Ala Ser Ser Ser Tyr Met Pro Gly Lys His Ser Ile
245 250 255
Gln Ala Arg Asp His Thr Gly Ser Met Gln His Cys Pro Ala Gln Arg
260 265 270

7/13

Cys Gln Ala Ala Ala Ser His Ser Pro Arg Met Leu Pro Tyr Glu Asn

275

280

285

Thr Asn Ser Glu Lys Pro Asp Pro Thr Lys Pro Asp Glu Lys Asp Val

290

295

300

Trp Gln Asn Glu Trp Tyr Ile Gly Glu Tyr Ser Arg Gln Ala Val Glu

305

310

315

320

Asp Val Leu Met Lys Glu Asn Lys Asp Gly Thr Phe Leu Val Arg Asp

325

330

335

Cys Ser Thr Lys Ser Lys Ala Glu Pro Tyr Val Leu Val Val Phe Tyr

340

345

350

Gly Asn Lys Val Tyr Asn Val Lys Ile Arg Phe Leu Glu Ser Asn Gln

355

360

365

Gln Phe Ala Leu Gly Thr Gly Leu Arg Gly Asn Glu Met Phe Asp Ser

370

375

380

Val Glu Asp Ile Ile Glu His Tyr Thr Tyr Phe Pro Ile Leu Leu Ile

385

390

395

400

Asp Gly Lys Asp Lys Ala Ala Arg Arg Lys Gln Cys Tyr Leu Thr Gln

405

410

415

Pro Leu Pro Leu Ala Arg Leu Leu Leu Thr Gln Tyr Ser Ser Gln Ala

420

425

430

Leu His Glu

435

<210> 3

<211> 1129

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1).. (1128)

<300>

<301> Goitsuka R., et al.

<302> A BASH/SLP-76-related adaptor protein MIST/Clink involved in IgE
receptor-mediated mast cell degranulation

<303> Int. Immunol.

<304> 12

<305> 4

<306> 573-580

<307> 2000

<308> GenBank/AB021220

<309> 2000-05-26

<400> 3

ttc cag aac ttc agt ctg cca aaa aac agg tca tgg cct cgc atc aat 48

Phe Gln Asn Phe Ser Leu Pro Lys Asn Arg Ser Trp Pro Arg Ile Asn

1 5 10 15

agt gcc aca ggc cag tac cag agg atg aac aag cct ctt cta gac tgg 96

Ser Ala Thr Gly Gln Tyr Gln Arg Met Asn Lys Pro Leu Leu Asp Trp

20 25 30

gaa aga aac ttt gct gca gtc ctg gat gga gca aaa ggc cac agt gat 144

Glu Arg Asn Phe Ala Ala Val Leu Asp Gly Ala Lys Gly His Ser Asp

35 40 45

gat gac tat gat gac cct gag ctt cgg atg gaa gag aca tgg cag tcg 192

Asp Asp Tyr Asp Asp Pro Glu Leu Arg Met Glu Glu Thr Trp Gln Ser

50

55

60

att aaa att tta cca gcc cgg cct ata aag gaa tct gaa tat gca gat	240
Ile Lys Ile Leu Pro Ala Arg Pro Ile Lys Glu Ser Glu Tyr Ala Asp	
65 70 75 80	
aca cac tat ttc aag gtt gca atg gac act ccc ctt ccg tta gac acc	288
Thr His Tyr Phe Lys Val Ala Met Asp Thr Pro Leu Pro Leu Asp Thr	
85 90 95	
agg acc tct atc tcc att gga cag ccg acc tgg aac aca cag acg agg	336
Arg Thr Ser Ile Ser Ile Gly Gln Pro Thr Trp Asn Thr Gln Thr Arg	
100 105 110	
ttg gaa aga gtg gac aaa ccc att tcc agg gac gtc aga agc caa aac	384
Leu Glu Arg Val Asp Lys Pro Ile Ser Arg Asp Val Arg Ser Gln Asn	
115 120 125	
att aaa gga gat gca tcc gta aga aag aac aag att cct tta cca cct	432
Ile Lys Gly Asp Ala Ser Val Arg Lys Asn Lys Ile Pro Leu Pro Pro	
130 135 140	
cct cgg cct ctc ata aca ctt ccg aag aag tac caa ccc ttg ccc cct	480
Pro Arg Pro Leu Ile Thr Leu Pro Lys Lys Tyr Gln Pro Leu Pro Pro	
145 150 155 160	
gag ccg gag agc agc agg cca cct tta tct cag aga cac acc ttt cca	528
Glu Pro Glu Ser Ser Arg Pro Pro Leu Ser Gln Arg His Thr Phe Pro	
165 170 175	
gaa gtc cag gga atg ccc agt cag ata agc tta agg gac tta agt gag	576
Glu Val Gln Gly Met Pro Ser Gln Ile Ser Leu Arg Asp Leu Ser Glu	
180 185 190	
gtc ctt gaa gca gaa aaa gtt cct cat aac cag agg aag cct gaa tca	624
Val Leu Glu Ala Glu Lys Val Pro His Asn Gln Arg Lys Pro Glu Ser	
195 200 205	
act cat ctg tta gaa aac caa aat act caa gag att cca ctt gcc att	672

10/13

Thr His Leu Leu Glu Asn Gln Asn Thr Gln Glu Ile Pro Leu Ala Ile
210 215 220
agc agt tct tca ttc acg aca agc aac cac agt gtg caa aac aga gat 720
Ser Ser Ser Ser Phe Thr Thr Ser Asn His Ser Val Gln Asn Arg Asp
225 230 235 240
cat aga gga ggc atg cag ccc tgt tct cct cag aga tgc cag cct cca 768
His Arg Gly Gly Met Gln Pro Cys Ser Pro Gln Arg Cys Gln Pro Pro
245 250 255
gcc agc tgc agc cct cac gaa aat ata ctg ccc tat aaa tac aca agc 816
Ala Ser Cys Ser Pro His Glu Asn Ile Leu Pro Tyr Lys Tyr Thr Ser
260 265 270
tgg aga cca cct ttc ccc aaa agg tct gat aga aag gat gtc cag cac 864
Trp Arg Pro Pro Phe Pro Lys Arg Ser Asp Arg Lys Asp Val Gln His
275 280 285
aat gaa tgg tac att gga gaa tac agc cgc cag gca gtg gaa gag gca 912
Asn Glu Trp Tyr Ile Gly Glu Tyr Ser Arg Gln Ala Val Glu Glu Ala
290 295 300
ttc atg aag gag aac aag gat ggt agt ttc ttg gtc cga gat tgt tcc 960
Phe Met Lys Glu Asn Lys Asp Gly Ser Phe Leu Val Arg Asp Cys Ser
305 310 315 320
aca aaa tcc aag gaa gag ccc tat gtt ttg gct gtg ttt tat gag aac 1008
Thr Lys Ser Lys Glu Glu Pro Tyr Val Leu Ala Val Phe Tyr Glu Asn
325 330 335
aaa gtc tac aat gta aaa atc cgc ttc ctg gag agg aat cag cag ttt 1056
Lys Val Tyr Asn Val Lys Ile Arg Phe Leu Glu Arg Asn Gln Gln Phe
340 345 350
gcc ctg ggg aca gga ctc aga gga gat gag aag ttt gat tca gta gaa 1104
Ala Leu Gly Thr Gly Leu Arg Gly Asp Glu Lys Phe Asp Ser Val Glu

11/13

355

360

365

gac atc atc gaa cac tac aag aat t

1129

Asp Ile Ile Glu His Tyr Lys Asn

370

375

<210> 4

<211> 376

<212> PRT

<213> Homo sapiens

<400> 4

Phe Gln Asn Phe Ser Leu Pro Lys Asn Arg Ser Trp Pro Arg Ile Asn

1

5

10

15

Ser Ala Thr Gly Gln Tyr Gln Arg Met Asn Lys Pro Leu Leu Asp Trp

20

25

30

Glu Arg Asn Phe Ala Ala Val Leu Asp Gly Ala Lys Gly His Ser Asp

35

40

45

Asp Asp Tyr Asp Asp Pro Glu Leu Arg Met Glu Glu Thr Trp Gln Ser

50

55

60

Ile Lys Ile Leu Pro Ala Arg Pro Ile Lys Glu Ser Glu Tyr Ala Asp

65

70

75

80

Thr His Tyr Phe Lys Val Ala Met Asp Thr Pro Leu Pro Leu Asp Thr

85

90

95

Arg Thr Ser Ile Ser Ile Gly Gln Pro Thr Trp Asn Thr Gln Thr Arg

100

105

110

Leu Glu Arg Val Asp Lys Pro Ile Ser Arg Asp Val Arg Ser Gln Asn

115

120

125

Ile Lys Gly Asp Ala Ser Val Arg Lys Asn Lys Ile Pro Leu Pro Pro

130	135	140	
Pro Arg Pro Leu Ile Thr Leu Pro Lys Lys Tyr Gln Pro Leu Pro Pro			
145	150	155	160
Glu Pro Glu Ser Ser Arg Pro Pro Leu Ser Gln Arg His Thr Phe Pro			
	165	170	175
Glu Val Gln Gly Met Pro Ser Gln Ile Ser Leu Arg Asp Leu Ser Glu			
	180	185	190
Val Leu Glu Ala Glu Lys Val Pro His Asn Gln Arg Lys Pro Glu Ser			
	195	200	205
Thr His Leu Leu Glu Asn Gln Asn Thr Gln Glu Ile Pro Leu Ala Ile			
	210	215	220
Ser Ser Ser Ser Phe Thr Thr Ser Asn His Ser Val Gln Asn Arg Asp			
225	230	235	240
His Arg Gly Gly Met Gln Pro Cys Ser Pro Gln Arg Cys Gln Pro Pro			
	245	250	255
Ala Ser Cys Ser Pro His Glu Asn Ile Leu Pro Tyr Lys Tyr Thr Ser			
	260	265	270
Trp Arg Pro Pro Phe Pro Lys Arg Ser Asp Arg Lys Asp Val Gln His			
	275	280	285
Asn Glu Trp Tyr Ile Gly Glu Tyr Ser Arg Gln Ala Val Glu Glu Ala			
	290	295	300
Phe Met Lys Glu Asn Lys Asp Gly Ser Phe Leu Val Arg Asp Cys Ser			
305	310	315	320
Thr Lys Ser Lys Glu Glu Pro Tyr Val Leu Ala Val Phe Tyr Glu Asn			
	325	330	335
Lys Val Tyr Asn Val Lys Ile Arg Phe Leu Glu Arg Asn Gln Gln Phe			
	340	345	350
Ala Leu Gly Thr Gly Leu Arg Gly Asp Glu Lys Phe Asp Ser Val Glu			

13/13

355

360

365

Asp Ile Ile Glu His Tyr Lys Asn

370

375